carfilzomib + lenalidomide + dexamethasone

Carfilzomib + lenalidomide + dexamethasone is a three-drug combination regimen primarily used for the treatment of relapsed or refractory multiple myeloma. Carfilzomib is a proteasome inhibitor that irreversibly binds to the 20S proteasome, leading to accumulation of proteins within cancer cells and inducing apoptosis. Lenalidomide is an immunomodulatory agent that inhibits tumor cell proliferation and modulates the immune response. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and anti-myeloma effects; it enhances the efficacy of both carfilzomib and lenalidomide. This combination has demonstrated improved progression-free survival compared to standard regimens in clinical trials[5][6][7].

Brand names

Kyprolis (carfilzomib)Revlimid (lenalidomide)Decadron (dexamethasone)

Other names

KRd regimencarfilzomib, lenalidomide, and dexamethasone